Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Asia
Pharma
BIO-WuXi, Takeda, FDA-Carvykti—Fierce Pharma Asia
WuXi AppTec left BIO amid alleged biosecurity concerns. Takeda will close a gene therapy plant. The FDA flagged early deaths in a Carvykti trial.
Angus Liu
Mar 15, 2024 10:15am
BeiGene finally snags FDA approval for PD-1 drug Tevimbra
Mar 15, 2024 8:39am
BIO pledges support to bill targeting Chinese biotechs
Mar 13, 2024 6:09pm
Eisai, Sumitomo, Kyowa Kirin and more—Fierce Pharma Asia
Mar 8, 2024 9:42am
BeiGene, BMS, AZ-FibroGen and more—Fierce Pharma Asia
Mar 1, 2024 8:55am
AstraZeneca finally drops roxadustat US rights
Feb 27, 2024 11:28am